The company said revenues from its clinical lab services rose 9 percent because of high demand for certain molecular diagnostic services.
The study, which evaluated data from 65,000 women on 21 genes, identified new risk genes and those that confer no risk, and the findings may have clinical implications.
The company has installed Illumina's HiSeq X sequencing platform and expects to sequence 20,000 genomes by the end of next year.
The three-year trial used immunoassays and PCR testing, and found 335 Babesia microti positive samples among 89,153 blood donations.
The study, which is still ongoing, also provided support for a separate Phase 2/3 trial of a targeted treatment for the neurodevelopmental disorder.
In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.
Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.
The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.
Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.